Chantal LaForest
Papers
1
Total Citations
86
H-Index
1
About
Chantal LaForest is a leading voice in pharmacovigilance innovation, with her work centered on the intersection of drug safety and artificial intelligence. Her most-cited paper, "Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing" (2018, 86 citations), is a landmark study that demonstrated how AI and robotic process automation can transform the labor-intensive, high-cost domain of adverse event case processing. By piloting these technologies, LaForest provided a practical blueprint for automating a key cost driver in pharmaceutical safety operations, offering a scalable solution that improves both efficiency and accuracy. Her contributions have positioned her as a pioneer in modernizing pharmacovigilance, helping to shift the industry from manual, error-prone workflows toward intelligent, automated systems. This work not only reduces operational burdens but also enhances patient safety by enabling faster, more reliable detection of adverse events. LaForest’s research continues to influence regulatory and industry discussions on digital transformation in drug safety, making her a vital figure for students and researchers interested in the future of pharmacovigilance.
Research Focus
Key Achievements
Top Papers
- 1